Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Dec:14:15-23.
doi: 10.1016/j.ebiom.2016.10.034. Epub 2016 Oct 23.

Therapeutic Targeting of Autophagy

Christina G Towers  1 , Andrew Thorburn  2
Affiliations
Review

Therapeutic Targeting of Autophagy

Christina G Towers et al. EBioMedicine. 2016 Dec.

Abstract

Autophagy is a catabolic process that facilitates nutrient recycling via degradation of damaged organelles and proteins through lysosomal mediated degradation. Alterations in this complex, and tightly regulated process, lead to disease. Autophagy is widely accepted as cytoprotective against neurodegenerative diseases and a variety of clinical interventions are moving forward to increase autophagy as a therapeutic intervention. Autophagy has both positive and negative roles in cancer and this has led to controversy over whether or how autophagy manipulation should be attempted in cancer therapy. Nevertheless, cancer is the disease where most current activity in trying to manipulate autophagy for therapy is taking place and dozens of clinical trials are using autophagy inhibition with Chloroquine or Hydroxychloroquine in combination with other drugs for the treatment of multiple neoplasms. Here, we review recent literature implicating autophagy in neurodegenerative diseases and cancer and highlight some of the opportunities, controversies and potential pitfalls of therapeutically targeting autophagy.

Keywords: Autophagy; Cancer; Clinical trials; Neurodegenerative disease.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Interventions that target autophagy. Macroautophagy is controlled by nutrient availability via regulation by mTORC1, which under conditions of nutrient availability can inhibit the formation of Ulk1/2 complexes. Ulk complexes facilitate Beclin-1 complex formation and phagaphore initiation. Phagaphore elongation is then mediated by LC3-PE conjugation and ATG5-12 conjugation. Finally, double membrane autophagasomes fuse with lysosomes to form autophagolysosomes resulting in degradation of autophagosome contents by lysosomal hydrolases. A number of pharmacological and naturally occurring agents have been designed/discovered that target this pathway allowing interventions that upregulate and down regulate autophagy.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Akin D., Wang S.K., Habibzadegah-Tari P., Law B., Ostrov D., Li M., Yin X.-M., Kim J.-S., Horenstein N., Dunn W.A. A novel ATG4B antagonist inhibits autophagy and has a negative impact on osteosarcoma tumors. Autophagy. 2014;10:2021–2035. - PMC - PubMed
    1. Amaravadi R.K. Transcriptional regulation of autophagy in RAS-driven cancers. J. Clin. Invest. 2015;125:1393–1395. - PMC - PubMed
    1. Arias E., Koga H., Diaz A., Mocholi E., Patel B., Cuervo A.M. Lysosomal mTORC2/PHLPP1/Akt regulate chaperone-mediated autophagy. Mol. Cell. 2015;59:270–284. - PMC - PubMed
    1. Baginska J., Viry E., Berchem G., Poli A., Noman M.Z., Van Moer K., Medves S., Zimmer J., Oudin A., Niclou S.P., Bleackley R.C., Goping I.S., Chouaib S., Janji B. Granzyme B degradation by autophagy decreases tumor cell susceptibility to natural killer-mediated lysis under hypoxia. Proc. Natl. Acad. Sci. U. S. A. 2013;110:17450–17455. - PMC - PubMed
    1. Bago R., Malik N., Munson M.J., Prescott A.R., Davies P., Sommer E., Shpiro N., Ward R., Cross D., Ganley I.G., Alessi D.R. Characterization of VPS34-IN1, a selective inhibitor of Vps34, reveals that the phosphatidylinositol 3-phosphate-binding SGK3 protein kinase is a downstream target of class III phosphoinositide 3-kinase. Biochem. J. 2014;463:413–427. - PMC - PubMed

MeSH terms